Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grifols ADR Representing One Non-Voting Ord Shs Class B GRFS

Healthcare Biotechnology
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale... see more

Recent & Breaking News (NDAQ:GRFS)

Grifols introduces the AlphaKit® QuickScreen, a novel point-of-care screening device to detect alpha1-antitrypsin (AAT) deficiency, a leading cause of genetic emphysema / COPD in adults

PR Newswire September 9, 2013

Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®

Business Wire August 28, 2013

California State Legislature recognizes Grifols for its Decennial Anniversary in California

PR Newswire August 12, 2013

Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University

Canada NewsWire July 18, 2013

Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency

Canada NewsWire May 22, 2013

Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency

PR Newswire May 22, 2013

Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin(TM)

Business Wire May 21, 2013

Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013

PR Newswire April 5, 2013

Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection

PR Newswire March 6, 2013

PROLASTIN® celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency

PR Newswire February 5, 2013